Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid

British Journal of Pharmacology

Volumn 124, Issue 2, 1998, Pages 391-399

  Harris, C A ^a   Miranda, A F ^a   Tanguay, J J ^a   Boegman, R J ^a   Beninger, R J ^a   Jhamandas, K ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Endogenous kynurenic acid; Neurotoxicity; Nicotinylalanine; Quinolinic acid

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR; ALANINE DERIVATIVE; AMINO ACID RECEPTOR BLOCKING AGENT; KYNURENIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; NEUROTOXIN; NICOTINYLALANINE; PROBENECID; QUINOLINIC ACID; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE DEHYDROGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; CORPUS STRIATUM; HUNTINGTON CHOREA; MALE; NERVE CELL NECROSIS; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0031836667     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0701834     Document Type: Article

References (44)

1. BEAL, M.F., KOWALL, N.W., ELLISON, E.W., MAZUREK, M.F., SWARTZ, K.J., SWARTZ, K.J. & MARTIN, J.B. (1986). Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature, 321, 168-171.
2. BEAL, M.F., MATSON, W.R., SWARTZ, K.J., GAMACHE, P.A. & BIRD, E.D. (1990). Kynurenine pathway measurements in Huntington's disease: evidence for reduced formation of kynurenic acid. J. Neurochem., 55, 1327-1339.
3. BEAL, M.F., MATSON, W.R., SWARTZ, K.J., GAMACHE, P.A. & BIRD, E.D. (1992). Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex. J. Neurol. Sci., 108, 80-87.
4. BOEGMAN, R., EL-DEFRAWY, S.R., JHAMANDAS, K., BENINGER. R.J. & LUDWIN, S.K. (1985). Quinolinic acid neurotoxicity in the nucleus basalis antagonized by kynurenic acid. Neurobiol. Aging, 6, 331-336.
5. BOEGMAN, R.J. & PARENT, A. (1988). Differential sensitivity of neuropeptide Y, somatostalin, and NADPH-diaphorase containing neurons in rat cortex and striatum to quinolinic acid. Brain Res., 445, 358-362.
6. CARPENEDO, R., CHIARREGI, A., RUSSI, P., LOMBARDI, G., CARLA, V., PCLLICIARI, R., MATTOLI, L., & MORONI, R. (1994). Inhibitors of kynurenine hydroxylase and kynureninase increase cerebral formation of kynurenate and have sedative and anticonvulsant activities. Neuroscience, 61, 237-243.
7. CHOI, D.W. (1988). Glutamate neurotoxicity and diseases of the nervous system. Neuron, 1, 623-634.
8. COCKHILL, J., JHAMANDAS, K., BOEGMAN, R.J. & BENINGER, R.J. (1992). Action of picolinic acid and structurally related pyridine carboxylic acids on quinolinic acid-induced cortical cholinergic damage. Brain Res., 599, 57-63.
9. CONNICK, J.H., HEYWOOD, G.C., SILLS, G.J., THOMPSON, G.G., BRODIE, M.J. & STONE, T.W. (1992). Nicotinylalanine increases cerebral kynurenic acid content and has anticonvulsant activity. Gen. Pharmacol., 23, 235-239.
10. CONNOP, B.P., BOEGMAN, R.J., JHAMANDAS, K. & BENINGER, R.J. (1995). Excitotoxic action of NMDA agonists on nigrostriatal dopaminergic neurons: Modulation by inhibition of nitric oxide synthesis. Brain Res., 676, 124-132.
11. DAVIES, S.W. & ROBERTS, P.J. (1987). No evidence for preservation of somatostatin-containing neurons after intrastriatal injection of quinolinic acid. Nature, 327, 326-329.
12. DECKER, V.L., BROWN, R.R. & PRICE, J.M. (1963). Studies on the biological activity of nicotinylalanine, an analogue of kynurenine. J. Biol. Chem., 238, 1049-1053.
13. EL-DEFRAWY, S.R., COLOMA, F., JHAMANDAS, K., BOEGMAN, R.J., BENINGER, R.J. & WIRSCHING, B.A. (1985). Functional and neurochemical cortical cholinergic lesions of the nucleus basalis magnocellularis in the rat. Neurobiol. Aging, 6, 325-330.
14. FIGUEREDO-CARDENAS, G., ANDERSON, K.D., CHEN, Q., VEENMAN, C.L. & REINER, A. (1994). Relative survival of striatal projection neurons and interneurons after striatal injection of quinolinic acid. Exp. Neurol., 129, 37-56.
15. FOSTER, A.C., VEZZANI, A., FRENCH, E.D. & SCHWARCZ, R. (1984). Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid. Neurosci. Lett., 48, 273-278.
16. JHAMANDAS, K., BOEGMAN, R.J., BENINGER, R.J. & BIALIK, M. (1990). Quinolate-induced cortical cholinergic damage: modulation by tryptophan metabolites. Brain Res., 529, 185-191.
17. KALISCH, B.E., JHAMANDAS, K., BOEGMAN, R.J. & BENINGER, R.J. (1994). Picolinic acid protects against quinolinic acid-induced depletion of NADPH-diaphorase containing neurons in the rat striatum. Brain Res., 668, 1-8.
18. LUTHMAN, J., VANERMAN, E., FREDERIKSSON, G. & FORNSTEDTWALLIN, B. (1996). Regulation of quinolinic acid in the normal rat brain by kynurenine pathway precursors. Adv. Exp. Med. Biol., 398, 229-239.
19. MILLER, J.M., MACGARVEY, V. & BEAL, M.F. (1992). The effect of peripheral loading with kynurenine and probenecid on extra-cellular kynurenic acid concentrations. Neurosci. Lett., 146, 115-118.
20. MIRANDA, A.F., BOEGMAN, R.J., BENINGER, R.J. & JHAMANDAS, K.J. (1997). Protection against quinolinic acid-mediated excitotoxicity in nigrostriatal dopaminergic neurons by endogenous kynurenic acid. Neuroscience, 78, 967 975.
21. MORONI, F., RUSSI, P., GALLO-MEZO, M.A., MONETI, G. & PLLICCIARI, R. (1991). Modulation of quinolinic and kynurenic acid contents in the rat brain: effects of endotoxins and nicotinylalanine. J. Neurochem., 57, 1630-1635.
22. OLNEY, J.W. (1990). Excitotoxic amino acids and neuropsychiatric disorders. Annu. Rev. Pharmacol. Toxicol., 30, 47-71.
23. PERKINS, M.N. & STONE, T.W. (1982). An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res., 247, 184-187.
24. ROBERTS, R.C., AHN, A., SWARTZ, K.J., BEAL, M.F. & DIFIGLIA, M. (1993). Intrastriatal injection of quinolinic acid or kainic acid: differential patterns of cell survival and the effects of data analysis on outcome. Exp. Neurol., 124, 274-282.
25. ROBERTS, R.C., DU, F., MCCARTHY, K.E., OKUNO, E. & SCHWARCZ, R. (1992). Immunocytochemical localization of kynurenine aminotransferasc in the rat striatum: A light and electron microscopic study. J. Comp. Neurol., 326, 82-90.
26. ROBERTS, R.C., MCCARTHY, K.E., DU, F., OKUNO, E. & SCHWARCZ, R. (1995). 3-Hydroxyanthranilic acid oxygenasecontaining astrocytic processes surround glutamate containing axon terminals in the rat striatum. J. Neurosci., 15, 1150-1161.
27. ROBINSON, M.B., SCHULTE. M.K., FREUND, R.K., JOHNSON, R.I., & KOERNER, J.R. (1985). Structure function relationships to kynurenic acid analogues at excitatory pathways in the rat hippocampal slice. Brain Res., 361, 19-24.
28. ROTHMAN, S.M. & OLNEY, J.W. (1986). Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann. Neurol., 19, 105-111.
29. RUSSI, P., ALESIANI, M., LOMBARDI, G., DAVOLIO, P., PELLICCIARI, R. & MORONI, E. (1992). Nicotinylalanine increases the formation of kynurenic acid in the brain and antagonizes convulsions. J. Neurochem., 59, 2076-2080.
30. RUZICKA, B.B. & JHAMANDAS, K. (1990). Elevation of Metenkephalin immunoreactivity in the rat striatum and globus pallidus following the focal injection of excitotoxins. Brain Res., 536, 227-239.
31. SANTAMARIA, A., RIOS, C., SOLIS-HERNANDEZ, ORDAZ-MORENO, J., GONZALEZ-REYNOSO, L., ALTAGRACIA, M. & KRAVZOV, J. (1996). Systemic DL-kynurenine and probenecid pretreatment attenuates quinolinic acid-induced neurotoxicity in rats. Neuropharmacoloy, 32, 25-28.
32. SCHWARCZ, R. (1993). Metabolism and function of brain kynurenines. Biochem. Soc. Trans., 21, 77-82.
33. SCHWARCZ, R., FOSTER, A.C., FRENCH, E.D., WHETSELL, F.R.W.O. & KÖHLER, C. (1984). Excitotoxic models of neurodcgenerative disorders. Life Sci., 35, 19-32.
34. SCHWARCZ, R., WHETSELL, W.O. & MANGANO, R.M. (1993). Quinolinic acid: an endogenous metabolite that produces axonsparing lesions in rat brain. Science (Washington, D.C.), 219, 316-319.
35. SIMS, K.L., KAUFFMAN, F.C., JOHNSON, E.C. & PICKEL, V.M. (1974). Cytochemical localization of brain nicotinamide adenine dinucleotide phosphate (oxidized)-dependent dehydrogenases. J. Histochem. Cytochem., 22, 7-19.
36. SPECIALE, C., WU, H.-Q., CINI, M., MARCONI, M., VARASI, M. & SCHWARCZ, R. (1993). On the production and disposition of quinolinic acid in rat brain and liver slices. J. Neurochem., 60, 212-218.
37. STONE, T.W. (1993). Neuropharmacology of quinolinic and kynurenic acid. Pharmacol. Rev., 45, 310-367.
38. STONE, T.W. & PERKINS, M.N. (1981). Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. Eur. J. Pharmacol., 72, 411-412.
39. SWARTZ, K.J., DURING, M.J., FREESE, A. & BEAL, M.F. (1990). Cerebral synthesis and release of kynurenic acid: an endogenous antagonist of excitatory amino acid receptors. J. Neurosci., 10, 2965-2973.
40. URENJAK, J., OBRENOVITCH, T.P. & AILKN, E. (1997). Effect of kynurenine and probenecid on depolarisations evoked by NMDA. Naunyn-Schmiederbertgs Arch. Pharmacol., 355, 36-42.
41. VESCEI, L., MILLER, J., MACGARVEY, U. & BEAL, M.F. (1992). Effects of kynurenine and probenecid on plasma and brain tissue concentrations of kynurenic acid. Neurodegeneration, 1, 17-26.
42. WINN, P., STONE, T.W., LATIMER, M., HASTINGS, M.H. & CLARK, A.J.M. (1991). A comparison of excitotoxic lesions of the basal forebrain by kainate, quinolinate, ibotenate, N-methyl-D-aspartate or quisqualate, and the effects on toxicity of 2-amino-5-phosphonovaleric acid and kynurenic acid in the rat. Br. J. Pharmacol., 102, 904-908.
43. WIRSCHING, B.A., BENINGER, R.J., JHAMANDAS, K., BOEGMAN, R.J. & BIALIK, M. (1989). Kynurenic acid protects against the neurochemical and behavioural effects of unilateral quinolinic acid injections into the nucleus basalis of rats. Behav. Neurosci., 103, 90-97.
44. WU, H.-Q., UNGERSTEDT, U. & SCHWARCZ, R. (1992). Regulation of kynurenic acid synthesis studied by microdialysis in the dorsal hippocampus of unanesthetized rats. Eur. J. Pharmacol., 213, 375-380.